PMID- 32329824
OWN - NLM
STAT- MEDLINE
DCOM- 20210329
LR  - 20210329
IS  - 2284-0729 (Electronic)
IS  - 1128-3602 (Linking)
VI  - 24
IP  - 7
DP  - 2020 Apr
TI  - Effects of miR-32 targeting PTEN on proliferation and apoptosis of myeloma cells.
PG  - 3509-3516
LID - 20810 [pii]
LID - 10.26355/eurrev_202004_20810 [doi]
AB  - OBJECTIVE: To explore the effects of micro ribonucleic acid (miR)-32 on the 
      proliferation and apoptosis of myeloma cells, and to verify whether it exerts its 
      function by targeting phosphatase and tensin homolog deleted on chromosome ten 
      (PTEN). PATIENTS AND METHODS: The differentially expressed miRNAs were screened 
      in healthy people and myeloma patients. The myeloma U266 cells transfected with 
      negative control (NC) were used as control group, those transfected with miR-32 
      inhibitor as transfection group, and those transfected with miR-32 inhibitor and 
      treated with PTEN inhibitor SF1670 as the transfection + inhibitor group. Then, 
      the cell proliferation and apoptosis in each group were detected using the 
      5-Ethynyl-2'-deoxyuridine (EdU) kit and terminal deoxynucleotidyl 
      transferase-mediated dUTP nick end labeling (TUNEL) assay, respectively. Finally, 
      the expressions of apoptosis-related proteins B-cell lymphoma-2 (Bcl-2), Bcl-2 
      homologous antagonist/killer (Bak), caspase-9, and survivin were detected. 
      RESULTS: The expressions of some miRNAs and genes in myeloma patients were 
      significantly different from those in healthy people. In myeloma patients, 
      miR-32, miR-126, miR-123, and miR-183 were significantly highly expressed, while 
      miR-5, miR-76, and miR-50 were remarkably lowly expressed. After myeloma U266 
      cells were transfected with the miR-32 inhibitor, the expression of miR-32 
      markedly declined. In addition, the mRNA expression of PTEN in myeloma cells rose 
      after transfection with the miR-32 inhibitor, and declined after addition of the 
      PTEN inhibitor SF1670, which were consistent with the results of Western 
      blotting. Besides, the proliferation ability of myeloma cells was evidently 
      weakened after transfection with the miR-32 inhibitor, while it was restored to a 
      certain extent after addition of the PTEN inhibitor SF1670. Moreover, the number 
      of apoptotic myeloma cells was remarkably larger after transfection with the 
      miR-32 inhibitor, while it was remarkably smaller after addition of the PTEN 
      inhibitor SF1670. The expressions of pro-apoptotic proteins Bak and caspase-9 in 
      myeloma cells were significantly increased after transfection with the miR-32 
      inhibitor (p<0.05), and significantly decreased after addition of the PTEN 
      inhibitor SF1670, while the expressions of anti-apoptotic proteins Bcl-2 and 
      survivin were opposite to those of Bak and caspase-9. CONCLUSIONS: MiR-32 
      targeting PTEN will have certain effects on the proliferation and apoptosis of 
      myeloma cells.
FAU - Sun, Y-Y
AU  - Sun YY
AD  - Department of Hematology, First Affiliated Hospital of Jinzhou Medical 
      University, Jinzhou, China. alm121001@163.com.
FAU - Pan, J
AU  - Pan J
FAU - Wei, W
AU  - Wei W
FAU - Yu, S-S
AU  - Yu SS
FAU - Mao, S-D
AU  - Mao SD
FAU - Zhang, N
AU  - Zhang N
FAU - Ai, L-M
AU  - Ai LM
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
RN  - 0 (MIRN32 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 0 (Phenanthrenes)
RN  - 0 (SF1670)
RN  - EC 3.1.3.67 (PTEN Phosphohydrolase)
RN  - EC 3.1.3.67 (PTEN protein, human)
SB  - IM
MH  - *Apoptosis/drug effects
MH  - Cell Line, Tumor
MH  - Cell Proliferation/drug effects
MH  - Humans
MH  - MicroRNAs/antagonists & inhibitors/*metabolism
MH  - Multiple Myeloma/drug therapy/*metabolism/pathology
MH  - PTEN Phosphohydrolase/antagonists & inhibitors/*metabolism
MH  - Phenanthrenes/pharmacology
EDAT- 2020/04/25 06:00
MHDA- 2021/03/30 06:00
CRDT- 2020/04/25 06:00
PHST- 2020/04/25 06:00 [entrez]
PHST- 2020/04/25 06:00 [pubmed]
PHST- 2021/03/30 06:00 [medline]
AID - 20810 [pii]
AID - 10.26355/eurrev_202004_20810 [doi]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2020 Apr;24(7):3509-3516. doi: 
      10.26355/eurrev_202004_20810.